CN118251226A - 治疗肌萎缩性侧索硬化症的方法以及其给药方案 - Google Patents

治疗肌萎缩性侧索硬化症的方法以及其给药方案 Download PDF

Info

Publication number
CN118251226A
CN118251226A CN202280074805.3A CN202280074805A CN118251226A CN 118251226 A CN118251226 A CN 118251226A CN 202280074805 A CN202280074805 A CN 202280074805A CN 118251226 A CN118251226 A CN 118251226A
Authority
CN
China
Prior art keywords
fasudil
als
patient
treatment
treatment period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074805.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·麦卡利斯特
S·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuerxi Pharmaceutical Co ltd
Original Assignee
Wuerxi Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuerxi Pharmaceutical Co ltd filed Critical Wuerxi Pharmaceutical Co ltd
Publication of CN118251226A publication Critical patent/CN118251226A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280074805.3A 2021-11-12 2022-11-10 治疗肌萎缩性侧索硬化症的方法以及其给药方案 Pending CN118251226A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278523P 2021-11-12 2021-11-12
US63/278,523 2021-11-12
PCT/US2022/049541 WO2023086468A1 (en) 2021-11-12 2022-11-10 Method of treating amyotrophic lateral sclerosis and dosing regimen for same

Publications (1)

Publication Number Publication Date
CN118251226A true CN118251226A (zh) 2024-06-25

Family

ID=86336738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074805.3A Pending CN118251226A (zh) 2021-11-12 2022-11-10 治疗肌萎缩性侧索硬化症的方法以及其给药方案

Country Status (7)

Country Link
US (1) US20240415846A1 (https=)
EP (1) EP4429667A4 (https=)
JP (1) JP2024543347A (https=)
CN (1) CN118251226A (https=)
CA (1) CA3236338A1 (https=)
MX (1) MX2024005745A (https=)
WO (1) WO2023086468A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025207476A1 (en) * 2024-03-25 2025-10-02 Woolsey Pharmaceuticals, Inc. Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US9980972B2 (en) * 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
US20180055887A1 (en) * 2016-08-23 2018-03-01 Academia Sinica Method for preparing induced mesenchymal stem cells and improving mesenchymal stem cell's characters and its applications
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia

Also Published As

Publication number Publication date
EP4429667A1 (en) 2024-09-18
CA3236338A1 (en) 2023-05-19
US20240415846A1 (en) 2024-12-19
MX2024005745A (es) 2024-05-28
WO2023086468A1 (en) 2023-05-19
JP2024543347A (ja) 2024-11-21
EP4429667A4 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
Hardiman et al. Amyotrophic lateral sclerosis
Fan et al. Chronic oxycodone induces axonal degeneration in rat brain
US20260098052A1 (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
US20250228868A1 (en) Method of treating amyotrophic lateral sclerosis
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
CN115916187A (zh) 治疗蛋白病相关的游荡的方法
US20230285409A1 (en) Methods of using rho kinase inhibitors to treat vascular dementia
US20230248739A1 (en) Methods of treating cortical dementia associated wandering
JP2008074852A (ja) 肝機能が低下した精神医学上の患者をパリペリドンで治療
CN118251226A (zh) 治疗肌萎缩性侧索硬化症的方法以及其给药方案
US20240197708A1 (en) Treatment of prodromal huntington disease
WO2024011094A1 (en) Regimen for treating amyotrophic lateral sclerosis having onset 24 months prior to treatment
WO2024081763A1 (en) Method of treating amyotrophic lateral sclerosis by oral administration of fasudil
EP4551227A1 (en) Treating amyotrophic lateral sclerosis having onset 24 months prior to treatment
WO2025160116A1 (en) Methods of treating amyotrophic lateral sclerosis by oral administration of fasudil
EP4415716A1 (en) Method of treating amyotrophic lateral sclerosis
WO2025207476A1 (en) Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination